Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India
Vishal Goyal(Chandigarh University), Jorge Alvar(Real Academia Española), Raman Mahajan, Temmy Sunyoto, Nathalie Strub‐Wourgaft(Drugs for Neglected Diseases Initiative), Manica Balasegaram(Global Antibiotic Research & Development Partnership), Krishna Pandey(Rajendra Memorial Research Institute of Medical Sciences), Fabiana Alves(Drugs for Neglected Diseases Initiative), Sakib Burza(Unknown), Caryn Bern(University of California, San Francisco), Sally Ellis(Drugs for Neglected Diseases Initiative), Pradeep Das(Rajendra Memorial Research Institute of Medical Sciences), Roshan Kamal Topno(Rajendra Memorial Research Institute of Medical Sciences), Vidya Nand Rabi Das(Rajendra Memorial Research Institute of Medical Sciences), Bhawna Sharma(Gilead Sciences (United States)), Suman Rijal(Nepal Cancer Hospital and Research Center), Nines Lima(Médecins Sans Frontières), Ravi Shankar Singh, Allen W. Hightower(Bangkok University), Shambhu Nath Singh
Cited by 25
Related Papers
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72
AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial
|Clinical Infectious Diseases|2022|53
An open source pharma roadmap
|PLoS Medicine|2017|52